Cargando…

Evaluation of dopamine D(3) receptor occupancy by blonanserin using [(11)C]-(+)-PHNO in schizophrenia patients

RATIONALE: Unlike other antipsychotics, our previous positron emission tomography (PET) study demonstrated that a single dose of blonanserin occupied dopamine D(3) as well as dopamine D(2) receptors in healthy subjects. However, there has been no study concerning the continued use of blonanserin. OB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakayori, Takeshi, Tateno, Amane, Arakawa, Ryosuke, Kim, Woo-chan, Okubo, Yoshiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062348/ https://www.ncbi.nlm.nih.gov/pubmed/33180175 http://dx.doi.org/10.1007/s00213-020-05698-3

Ejemplares similares

Comparison of Dopamine D(3) and D(2) Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [(11)C]-(+)-PHNO
por: Tateno, Amane, et al.
Publicado: (2018)

Striatal Dopamine D(2) Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia
por: Nishibe, Hironori, et al.
Publicado: (2020)

Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D(2) Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch
por: Tomita, Yoshiko, et al.
Publicado: (2022)

Effect of DL-Methylephedrine on Dopamine Transporter Using Positron Emission Tomography With [(18)F]FE-PE2I
por: Nogami, Tsuyoshi, et al.
Publicado: (2022)

Preferential binding to dopamine D(3) over D(2) receptors by cariprazine in patients with schizophrenia using PET with the D(3)/D(2) receptor ligand [(11)C]-(+)-PHNO
por: Girgis, Ragy R., et al.
Publicado: (2016)

Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan
por: Tateno, Amane, et al.
Publicado: (2017)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin, Tomomi, et al.
Publicado: (2013)

Suicide decline and improved psychiatric treatment status: longitudinal survey of suicides and serious suicide attempters in Tokyo
por: Otaka, Yasushi, et al.
Publicado: (2022)

Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
por: Sakai, Shintaro, et al.
Publicado: (2021)

Exploring regulation and function of dopamine D3 receptors in alcohol use disorder. A PET [(11)C]-(+)-PHNO study
por: Chukwueke, Chidera C., et al.
Publicado: (2021)

Multi-Atlas MRI-Based Striatum Segmentation for (123)I-FP-CIT SPECT (DAT-SPECT) Compared With the Bolt Method and SPECT-Atlas-Based Segmentation Method Toward the Accurate Diagnosis of Parkinson's Disease/Syndrome
por: Sohara, Koji, et al.
Publicado: (2021)

Effect of scan-time shortening on the (11)C-PHNO binding potential to dopamine D(3) receptor in humans and test–retest reliability
por: Matsunaga, Keiko, et al.
Publicado: (2023)

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study
por: Woo, Young Sup, et al.
Publicado: (2016)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

Influence of contact with schizophrenia on implicit attitudes towards schizophrenia patients held by clinical residents
por: Omori, Ataru, et al.
Publicado: (2012)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014)

S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION? AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY
por: Bahk, Won-Myong, et al.
Publicado: (2018)

The relationship between childhood trauma, dopamine release and dexamphetamine-induced positive psychotic symptoms: a [(11)C]-(+)-PHNO PET study
por: Dahoun, Tarik, et al.
Publicado: (2019)

Toward the Optimization of (+)-[(11)C]PHNO Synthesis: Time Reduction and Process Validation
por: Pfaff, Sarah, et al.
Publicado: (2019)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

Influence of Nicotine Metabolism Ratio on [(11)C]-(+)-PHNO PET Binding in Tobacco Smokers
por: Di Ciano, Patricia, et al.
Publicado: (2018)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

PM429. Comparison of haloperidol and blonanserin on development of dopamine supersensitivity after chronic treatment
por: Hashimoto, Takashi, et al.
Publicado: (2016)

Presentation of Smoking-Associated Cues Does Not Elicit Dopamine Release after One-Hour Smoking Abstinence: A [(11)C]-(+)-PHNO PET Study
por: Chiuccariello, Lina, et al.
Publicado: (2013)

Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [(11)C]PHNO PET
por: Rabiner, Eugenii A., et al.
Publicado: (2021)

Association of dopamine D(2/3) receptor binding potential measured using PET and [(11)C]-(+)-PHNO with post-mortem DRD(2/3) gene expression in the human brain
por: Komorowski, Arkadiusz, et al.
Publicado: (2020)

A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch
por: Hagikura, Minako, et al.
Publicado: (2023)

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone
por: Hori, Hikaru, et al.
Publicado: (2014)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi, Taro, et al.
Publicado: (2016)

PM430. Blonanserin reversed phencyclidine-induced novel object recognition deficit and induced cortical dopamine and acetylcholine efflux through dopamine D(3) receptor antagonism
por: Miyauchi, Masanori, et al.
Publicado: (2016)

PM498. Investigation of feelings toward taking blonanserin and risperidone in schizophrenia patients: part 2
por: Shoji, Yoshihisa, et al.
Publicado: (2016)

Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies
por: Murasaki, Mitsukuni, et al.
Publicado: (2021)

Simple and Sensitive Analysis of Blonanserin and Blonanserin C in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry and Its Application
por: Zheng, Yunliang, et al.
Publicado: (2014)

Reliable set-up for in-loop (11)C-carboxylations using Grignard reactions for the preparation of [carbonyl-(11)C]WAY-100635 and [(11)C]-(+)-PHNO()
por: Rami-Mark, Christina, et al.
Publicado: (2013)

A case of delusional parasitosis responded to blonanserin
por: Rathi, Anubhav, et al.
Publicado: (2018)

The influence of conditioned stimuli on [(11)C]-(+)-PHNO PET binding in tobacco smokers after a one week abstinence
por: Di Ciano, Patricia, et al.
Publicado: (2021)

Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2017)

A Simple and Sensitive HPLC-MS/MS Assay for the Quantitation of Blonanserin and N-Desethyl Blonanserin in Rat Plasma and Its Application to Pharmacokinetic Study
por: Huang, Shan-qing, et al.
Publicado: (2022)

Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4h1n5j6ao6mhnua6h7dvui493e